AltheaDx, Inc., a San Diego, CA-based commercial stage molecular diagnostics company specializing in the field of personalized medicine, raised $27m in Series D funding.
The backers were not disclosed.
The company intends to use the funds to expands its sales force and marketing efforts to grow internationally.
Led by Jorge Garces, President and Chief Executive Officer, AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. Its IDgenetix® pharmacogenetic testing portfolio addresses cardiovascular disease, neuropsychiatric disorders and pain.
The company is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA.